AK105 Combined With Anlotinib in Patients With Cervical Cancer
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of AK105 (anti-PD-1 mab)
combined with Anlotinib Hydrochloride in the treatment of persistent, recurrent and
metastatic cervical cancer.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Zhengzhou University